63878-73-9

Usage

Uses

Used in Pharmaceutical Industry:
2-Fluoro-5-nitrobenzyl alcohol is used as a synthetic intermediate for the production of 2-fluoro-5-nitrobenzyl bromide, which is an important compound in the development of pharmaceuticals. The synthesis of this intermediate allows for the creation of new drugs with potential therapeutic applications.
Used in Chemical Synthesis:
In the field of chemical synthesis, 2-fluoro-5-nitrobenzyl alcohol is used as a precursor to synthesize 5-amino-2-fluorobenzyl alcohol. 2-FLUORO-5-NITROBENZYL ALCOHOL 96 can be further utilized in the development of various chemical products, showcasing the versatility of 2-fluoro-5-nitrobenzyl alcohol as a synthetic building block.
Used in Research and Development:
2-Fluoro-5-nitrobenzyl alcohol also finds application in research and development, where it can be employed to study the properties and reactivity of fluorinated aromatic compounds. This knowledge can be applied to design and develop new molecules with specific functionalities and applications in various industries, including pharmaceuticals, materials science, and agrochemicals.

InChI:InChI=1/C7H6FNO3/c8-7-2-1-6(9(11)12)3-5(7)4-10/h1-3,10H,4H2

Upstream product

• 27996-87-8 2-fluoro-5-nitrobenzaldehye 
• 7304-32-7 2-fluoro-5-nitrobenzoic acid 
• 84832-01-9 methyl 2,6-difluoro-3-nitrobenzoate 
• 83141-10-0 2,6-difluoro-3-nitrobenzoic acid 

Downstream Products

• 943513-41-5 C₃₃H₃₇FN₄O₃ 
• 943513-48-2 C₃₇H₄₁FN₄O₄ 
• 943513-42-6 C₃₃H₃₇FN₄O₄ 
• 943513-49-3 C₃₇H₄₁FN₄O₅ 
• 943513-43-7 C₃₄H₃₇FN₄O₅ 
• 943513-50-6 C₃₈H₄₁FN₄O₆ 
• 943513-44-8 C₃₃H₃₈FN₅O₃ 
• 943513-51-7 C₃₇H₄₂FN₅O₄ 
• 943513-45-9 C₃₄H₃₈FN₅O₄ 
• 943513-52-8 C₃₈H₄₂FN₅O₅ 
• 844891-43-6 2-[4-(5-amino-2-morpholin-4-ylbenzyloxy)-2-fluorophenyl]-1-cyclohexyl-1H-benzimidazole-5-carboxylic acid methyl ester 
• 943513-29-9 2-{4-[5-(4-chlorobutyrylamino)-2-morpholin-4-ylbenzyloxy]-2-fluorophenyl}-1-cyclohexyl-1H-benzimidazole-5-carboxylic acid methyl ester 
• 943513-54-0 1-cyclohexyl-2-{2-fluoro-4-[morpholin-4-yl-5-(2-oxopyrrolidin-1-yl)benzyloxy]phenyl}-1H-benzimidazole-5-carboxylic acid methyl ester 
• 943513-46-0 C₃₂H₃₃FN₄O₅ 

Relevant academic research and scientific papers

CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula (I), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. For Formula (I) compounds R1, R2, R3, Ar and Z are as defined in the specification. The inventive Formula (I) compounds are inhibitors of CK2 and find utility in any number of therapeutic applications, including but not limited to treatment of proliferative disorders such as cancer, inflammation and immunological disorders.

Influence of Fluorination on the Conformational Properties and Hydrogen-Bond Acidity of Benzyl Alcohol Derivatives

The effect of fluorination on the conformational and hydrogen-bond (HB)-donating properties of a series of benzyl alcohols has been investigated experimentally by IR spectroscopy and theoretically with quantum chemical methods (ab initio (MP2) and DFT (MPWB1K)). It was found that o-fluorination generally resulted in an increase in the HB acidity of the hydroxyl group, whereas a decrease was observed upon o,o′-difluorination. Computational analysis showed that the conformational landscapes of the title compounds are strongly influenced by the presence of o-fluorine atoms. Intramolecular interaction descriptors based on AIM, NCI and NBO analyses reveal that, in addition to an intramolecular OH...F interaction, secondary CH...F and/or CH...O interactions also occur, contributing to the stabilisation of the various conformations, and influencing the overall HB properties of the alcohol group. The benzyl alcohol HB-donating capacity trends are properly described by an electrostatic potential based descriptor calculated at the MPWB1K/6-31+G(d,p) level of theory, provided solvation effects are taken into account for these flexible HB donors.

New hits as antagonists of GPR103 identified by HTS

Preclinical data indicate that GPR103 receptor and its endogenous neuropeptides QRFP26 and QRFP43 are involved in appetite regulation. A high throughput screening (HTS) for small molecule GPR103 antagonists was performed with the clinical goal to target weight management by modulation of appetite. A high hit rate from the HTS and initial low confirmation with respect to functional versus affinity data challenged us to revise the established screening cascade. To secure high quality data while increasing throughput, the binding assay was optimized on quality to run at single concentration. This strategy enabled evaluation of a larger fraction of chemical clusters and singletons delivering 17 new compound classes for GPR103 antagonism. Representative compounds from three clusters are presented. One of the identified clusters was further investigated, and an initial structure-activity relationship study is reported. The most potent compound identified had a pIC50 of 7.9 with an improved ligand lipophilic efficiency.

HEPATITIS B ANTIVIRAL AGENTS

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

7-CHLORO-QUINOLIN-4-AMINE COMPOUNDS AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF DISEASES INVOLVING FORMATION OF AMYLOID PLAQUES AND/OR WHERE A DYSFUNCTION OF THE APP METABOLISM OCCURS

The present invention relates to compounds having the following Formula (I) for use in the prevention and/or the treatment of diseases involving formation of amyloid plaques and/or where a dysfunction of the APP metabolism occurs.

Optimized and convergent synthesis of potent anti-malarial aminoquinoline compounds: Easy access to analogs

Amodiaquine is one of the most active antimalarial 4-aminoquinoline. Previously we have described new analogs of amodiaquine and amopyroquine, in which the hydroxyl group was replaced by various amino groups and identified highly potent compounds. Here we

4H-1-benzopyrans by a tandem SN2-SNAr reaction

(Chemical Equation Presented) Treatment of 2-fluoro-5-nitrobenzyl bromide with active methylene compounds in the presence of excess potassium carbonate in acetone leads to the formation of highly functionalized 4H-1-benzopyrans by a tandem SN2-

Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders

Disclosed are pyrrolopyridazine compounds, methods of preparing such compounds, and their use for the treatment of proliferative, inflammatory, and other disorders.

3-`(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES AS P38 MAP KINASE INHIBITORS

Compounds of the formula (I), wherein: -X=Y- is selected from -CR2=CR3- and -CR2=N-; R1 is selected from H, halo, NRR', NHC(=O)R, NHC(=O)NRR', NH2SO2R, and C(=O)NRR'; R2 and R3 (where present) are independently selected from H, optionally substituted C1-7 alkyl, optionally substituted C5-20 aryl, optionally substituted C3-20 heterocyclyl, halo, amino, amido, hydroxy, ether, thio, thioether, acylamido, ureido and sulfonamino; R4 is an optionally substituted C5-20 aryl or C5-20 heteroaryl group; and R5 is selected from R5’, halo, NHR5’, C(=O)NHR5’, OR5’, SR5’, NHC(=O)R5’, NHC(=O)NHR5’, NHS(=O)R5’, wherein R5’ is H or C1-3 alkyl (optionally substituted by halo, NH2, OH, SH) are disclosed for use in therapy and for treating diseases ameliorated by inhibiting p38 MAP kinase.

Aniline derivatives possessing an inhibitory effect of nitric oxide synthase

Compounds represented by the general formula (1): ? (where R1is SR6or NR7R8, where R6is typically an alkyl group having 1-6 carbon atoms, R7is a hydrogen atom, an alkyl group having 1-6 carbon atoms or a nitro group, and R8is a hydrogen atom or an alkyl group having 1-6 carbon atoms; R2and R3are each typically a hydrogen atom or an alkyl group having 1-6 carbon atoms; R4is a hydrogen atom, an alkyl group having 1-6 carbon atoms or an amidino group of which the amine portion may be substituted by an alkyl or nitro group; R5is a hydrogen atom or an alkyl group having 1-6 carbon atoms; Y1, Y2, Y3and Y4which may be the same or different are each typically a hydrogen atom, a halogen atom or an alkoxy group having 1-6 carbon atoms; n and m are each an integer of 0 or 1), or possible stereoisomers or optically active forms of the compounds or pharmaceutically acceptable salts thereof. The compounds possess a potent nitric oxide synthase inhibiting activity and are useful as therapeutics of cerebrovascular diseases.